Published in Clin Drug Investig on January 01, 1998
Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog (2008) 1.83
Targeted vaccine selection in influenza vaccination. Dtsch Arztebl Int (2013) 1.36
Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother (2012) 1.18
Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One (2009) 1.04
Development of cross-protective influenza a vaccines based on cellular responses. Front Immunol (2015) 0.88
Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol (2006) 0.83
Evaluation of immunogenicity of the 2008-2009 seasonal influenza vaccines by microneutralization test. Korean J Pediatr (2012) 0.79
Adult preferences for influenza vaccines with lower likelihood of side effects. Hum Vaccin Immunother (2013) 0.78
Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks. Crit Care (2010) 0.78
Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial. Hum Vaccin Immunother (2015) 0.77
Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. Clin Infect Dis (2015) 0.76
CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults. Biol Blood Marrow Transplant (2010) 0.75
Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing. Med Microbiol Immunol (2013) 0.75
Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes. PLoS One (2016) 0.75
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet (1998) 16.30
Emerging marine diseases--climate links and anthropogenic factors. Science (1999) 10.22
A pandemic warning? Nature (1997) 8.70
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill (2012) 7.96
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol (2000) 6.96
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill (2012) 4.95
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods (1998) 3.67
Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) (2003) 3.16
Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill (2013) 2.97
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine (2002) 2.47
Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine (2003) 2.26
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies. Clin Diagn Lab Immunol (2000) 2.21
Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine (1998) 2.17
Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol (2000) 2.11
Haemorrhagic fever with renal syndrome. Lancet (1993) 2.09
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol (1997) 2.07
Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol (2000) 2.07
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Canine distemper virus from diseased large felids: biological properties and phylogenetic relationships. J Gen Virol (1996) 2.06
An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol (1999) 2.06
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med (1999) 2.01
Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol (2000) 1.95
Influenza types and patient population. Lancet (1995) 1.94
Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res (2004) 1.90
Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype. Lancet (2000) 1.87
Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant (2007) 1.83
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol (2001) 1.70
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother (2000) 1.66
Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis (1994) 1.65
Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol (2000) 1.61
Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol (1997) 1.61
Identification of virus causing recent seal deaths. Nature (1988) 1.58
Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine (1996) 1.55
Prevalence and association between herpes simplex virus types 1 and 2-specific antibodies in attendees at a sexually transmitted disease clinic. Int J Epidemiol (2001) 1.53
Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine (1989) 1.52
PCBs are a health risk for humans and wildlife. Science (2000) 1.51
Influenza virus: a master of metamorphosis. J Infect (2000) 1.50
Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol (1993) 1.50
The hanta hunting study: underdiagnosis of Puumala hantavirus infections in symptomatic non-travelling leptospirosis-suspected patients in the Netherlands, in 2010 and April to November 2011. Euro Surveill (2014) 1.49
Canine distemper virus--a morbillivirus in search of new hosts? Trends Microbiol (1997) 1.49
Recommendations for the use of inactivated influenza vaccines and other preventive measures. Vaccine (2001) 1.47
Mass die-Off of Caspian seals caused by canine distemper virus. Emerg Infect Dis (2001) 1.46
[Influenza pandemics: past and future]. Ned Tijdschr Geneeskd (1999) 1.42
Herpes simplex virus type 1 (HSV-1)--induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1. Ann Neurol (2000) 1.42
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis (1998) 1.42
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol (2000) 1.39
Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol (1998) 1.39
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol (2001) 1.38
Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol (1995) 1.38
Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. Intervirology (1983) 1.35
Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol (1990) 1.35
Characterization of fastidious adenovirus types 40 and 41 by DNA restriction enzyme analysis and by neutralizing monoclonal antibodies. Virus Res (1989) 1.34
An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Arch Virol (1990) 1.34
Combination of reverse transcriptase PCR analysis and immunoglobulin M detection on filter paper blood samples allows diagnostic and epidemiological studies of measles. J Clin Microbiol (2001) 1.34
Detection, typing, and subtyping of enteric adenoviruses 40 and 41 from fecal samples and observation of changing incidences of infections with these types and subtypes. J Clin Microbiol (1993) 1.31
Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated from pneumonia patients in The Netherlands. Virology (2001) 1.30
Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper/cytotoxic and CD8+ cytotoxic T cell clones. J Immunol (1989) 1.29
Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis (1997) 1.29
New clues to the emergence of flu pandemics. Nat Med (1998) 1.28
ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine (1999) 1.28
Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma. J Virol Methods (2000) 1.28
Antigen loading of MHC class I molecules in the endocytic tract. Traffic (2001) 1.27
A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine (2000) 1.26
Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS (1998) 1.24
Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol (1997) 1.24
Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains. Intervirology (1981) 1.23
Canine distemper virus in seals. Nature (1988) 1.22
Induction of neutralizing antibody in mice against poliovirus type II with monoclonal anti-idiotypic antibody. J Immunol (1985) 1.21
Characterization of phocid herpesvirus-1 and -2 as putative alpha- and gammaherpesviruses of North American and European pinnipeds. J Gen Virol (1996) 1.20
Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS (1993) 1.19
Feline immunodeficiency virus (FIV) infection in the cat as a model for HIV infection in man: FIV-induced impairment of immune function. AIDS Res Hum Retroviruses (1990) 1.19
Herpes simplex virus 1 transmission through corneal transplantation. Lancet (2001) 1.18
First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs. J Virol (1994) 1.17
A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. J Virol (1993) 1.16
Isolation and partial characterization of infectious molecular clones of feline immunodeficiency virus obtained directly from bone marrow DNA of a naturally infected cat. J Virol (1992) 1.15
The athymic nude rat. III. Natural cell-mediated cytotoxicity. Clin Immunol Immunopathol (1980) 1.15
Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J Gen Virol (1989) 1.15
Contaminant-related suppression of delayed-type hypersensitivity and antibody responses in harbor seals fed herring from the Baltic Sea. Environ Health Perspect (1995) 1.14
Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol (1995) 1.14
Serological and virological characterization of clinically diagnosed cases of measles in suburban Khartoum. J Clin Microbiol (2000) 1.13
Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand (1999) 1.11
An outbreak of West Nile fever among migrants in Kisangani, Democratic Republic of Congo. Am J Trop Med Hyg (1999) 1.11
Influenza immunization policies in Europe and the United States. Vaccine (1995) 1.11
Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr (2000) 1.09
Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine (1999) 1.08